Novo Nordisk A/S (NVO) Competitors $56.89 +1.44 (+2.60%) Closing price 08/22/2025 03:59 PM EasternExtended Trading$57.05 +0.16 (+0.28%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NVO vs. NVS, AZN, SNY, GSK, TAK, ARGX, ONC, BNTX, INSM, and TEVAShould you be buying Novo Nordisk A/S stock or one of its competitors? The main competitors of Novo Nordisk A/S include Novartis (NVS), AstraZeneca (AZN), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry. Novo Nordisk A/S vs. Its Competitors Novartis AstraZeneca Sanofi GSK Takeda Pharmaceutical argenex BeOne Medicines BioNTech Insmed Teva Pharmaceutical Industries Novartis (NYSE:NVS) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Do insiders and institutionals believe in NVS or NVO? 13.1% of Novartis shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is NVS or NVO a better dividend stock? Novartis pays an annual dividend of $2.60 per share and has a dividend yield of 2.0%. Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 1.4%. Novartis pays out 37.8% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 22.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Which has more risk and volatility, NVS or NVO? Novartis has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Is NVS or NVO more profitable? Novo Nordisk A/S has a net margin of 35.60% compared to Novartis' net margin of 25.64%. Novo Nordisk A/S's return on equity of 78.64% beat Novartis' return on equity.Company Net Margins Return on Equity Return on Assets Novartis25.64% 41.08% 16.83% Novo Nordisk A/S 35.60%78.64%24.51% Does the media prefer NVS or NVO? In the previous week, Novo Nordisk A/S had 95 more articles in the media than Novartis. MarketBeat recorded 119 mentions for Novo Nordisk A/S and 24 mentions for Novartis. Novartis' average media sentiment score of 1.34 beat Novo Nordisk A/S's score of 0.62 indicating that Novartis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 18 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Novo Nordisk A/S 54 Very Positive mention(s) 9 Positive mention(s) 42 Neutral mention(s) 9 Negative mention(s) 3 Very Negative mention(s) Positive Do analysts rate NVS or NVO? Novartis currently has a consensus price target of $123.50, suggesting a potential downside of 2.71%. Novo Nordisk A/S has a consensus price target of $81.00, suggesting a potential upside of 42.38%. Given Novo Nordisk A/S's higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than Novartis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novartis 2 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.09Novo Nordisk A/S 2 Sell rating(s) 11 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.06 Which has preferable earnings & valuation, NVS or NVO? Novo Nordisk A/S has lower revenue, but higher earnings than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovartis$50.32B5.33$11.94B$6.8718.48Novo Nordisk A/S$42.12B6.03$14.64B$3.6415.63 SummaryNovo Nordisk A/S beats Novartis on 11 of the 19 factors compared between the two stocks. Get Novo Nordisk A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVO vs. The Competition Export to ExcelMetricNovo Nordisk A/SLarge Cap Pharma IndustryMedical SectorNYSE ExchangeMarket Cap$254.42B$253.23B$5.81B$21.31BDividend Yield1.44%2.62%4.39%3.54%P/E Ratio15.6330.4431.3629.10Price / Sales6.034.71387.8754.41Price / Cash14.6113.5938.0224.09Price / Book9.937.529.535.47Net Income$14.64B$8.49B$3.26B$992.74M7 Day Performance8.51%2.66%2.14%2.67%1 Month Performance-19.57%0.31%3.22%2.35%1 Year Performance-58.46%-8.58%30.18%10.76% Novo Nordisk A/S Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVONovo Nordisk A/S4.6992 of 5 stars$56.89+2.6%$81.00+42.4%-58.5%$254.42B$42.12B15.6377,349Trending NewsAnalyst ForecastGap UpNVSNovartis1.8824 of 5 stars$123.95-0.2%$123.50-0.4%+7.1%$261.85B$50.32B18.0475,883News CoveragePositive NewsAnalyst DowngradeAZNAstraZeneca2.9594 of 5 stars$79.20+0.0%$86.00+8.6%-6.6%$245.67B$54.07B29.7894,300Positive NewsSNYSanofi3.8103 of 5 stars$49.94+0.3%$62.00+24.1%-8.6%$122.62B$44.46B12.0082,878Positive NewsGSKGSK2.8604 of 5 stars$39.09-0.7%$37.38-4.4%-5.8%$79.62B$40.10B18.0968,629Trending NewsAnalyst RevisionTAKTakeda Pharmaceutical1.2554 of 5 stars$15.12+0.8%N/A+2.8%$48.09B$30.09B50.3847,455News CoverageAnalyst DowngradeARGXargenex3.9909 of 5 stars$662.17+1.3%$746.81+12.8%+27.7%$40.52B$2.25B33.961,599News CoveragePositive NewsONCBeOne Medicines0.7522 of 5 stars$323.83+0.8%$330.89+2.2%N/A$35.49B$3.81B-187.1811,000BNTXBioNTech1.7458 of 5 stars$113.06-0.4%$135.80+20.1%+25.7%$27.16B$2.98B-70.626,772INSMInsmed4.0028 of 5 stars$128.02+0.2%$129.57+1.2%+67.3%$27.05B$363.71M-22.411,271Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionTEVATeva Pharmaceutical Industries3.2953 of 5 stars$18.24+2.1%$24.71+35.5%-0.5%$20.91B$16.54B-113.9736,830News CoveragePositive News Related Companies and Tools Related Companies Novartis Competitors AstraZeneca Competitors Sanofi Competitors GSK Competitors Takeda Pharmaceutical Competitors argenex Competitors BeOne Medicines Competitors BioNTech Competitors Insmed Competitors Teva Pharmaceutical Industries Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NVO) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novo Nordisk A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Novo Nordisk A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.